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Abstract 19 
The recent availability of high-throughput nucleic acid sequencing technologies has rapidly advanced 20 
approaches to analysing the role of the gut microbiome in governance of human health, including gut 21 
health, but also metabolic, cardiovascular, and mental health, inter alia.  Recent scientific studies suggest 22 
EI perturbations at population level cannot account for the current obesity epidemic, and significant work 23 
is investigating the potential role of the microbiome, and in particular its metabolic products, notably 24 
short-chain fatty acids, predominantly acetate, propionate and butyrate, the last of which is an energy 25 
source for the epithelium of the large intestine. The energy yield from dietary residues may be a significant 26 
factor influencing energy balance. This review posits that the contribution toward EI is governed by 27 
energy intake, diet composition (not just fibre), by the composition of the microbiome, and by levels of 28 
physical activity. Furthermore we hypothesize that these factors do not exist in a steady state, but rather 29 
are dynamic, with both short- and medium-term effects on appetite regulation. We suggest that existing 30 
modelling strategies for bacterial dynamics, specifically for growth in chemostat culture, are of utility in 31 
understanding the dynamic interplay of diet, activity and microbiomic oraganisation. Such approaches 32 
may be informative in optimising the application of dietary and microbial therapy to promote health. 33 
  34 
1. Overview 35 
The availability of high-throughput nucleic acid sequencing technologies has facilitated a range of new 36 
approaches to analysing the role of the gut microbiome in governance of human health (1). Modern 37 
techniques suggest a role for the microbiome maintenance of, not only gut health but, systemic 38 
conditions including cardiovascular health (2), mental health (3) and obesity (3). Despite wide media focus 39 
on excess energy intake (EI), recent scientific studies suggest EI perturbations at population level cannot 40 
account for the current obesity epidemic (4). The microbiome is responsible for production of a highly 41 
complex and highly dynamic metaexometabolome. Well known components of this include the short-42 
chain fatty acids acetate, propionate and butyrate, the last of which is an energy source for the epithelium 43 
of the large intestine (5), as well as an inhibitor of histone deacetylation (and thereby cell fate 44 
determination) (6). The energy yield from dietary residues entering the large intestine may account for as 45 
much as 10% of EI   (7) and is therefore a significant factor influencing energy balance. The guiding 46 
theme of this review is that this contribution toward EI is governed by energy intake, diet composition, 47 
the composition of the microbiome, and levels of physical activity. Furthermore we hypothesize that 48 
these factors do not exist in a steady state, but rather are dynamic, with both short- and medium-term 49 
effects on appetite regulation. There is therefore potential to modulate this component of EI through a 50 
range of modalities to promote health. 51 
 52 
2. Fibre /Dietary Residue 53 
2.1 Scope of definitions of dietary fibre 54 
Fibre is a component of diet which is highly complex and inconsistently defined. Approaches to the 55 
definition vary from the biochemical, to the physiological, to the functional. The Englyst definition, for 56 
example, LV ´non-starch polysaccharidesµ (8).  This is in line with other definitions within nutrition, 57 
although it is notable for the element of exclusion which places fibres in the general class of 58 
polysaccharides outwith the subclass of starches. Fig 1 provides top-level indication of the potential 59 
chemical complexity of this ontology (accessed from ChEBI 08.07.15). However, each endpoint within 60 
this ontology masks further factors, including the degree of polymerisation: the nature and extent of 61 
polymerisation of side-chains on any polysaccharide backbone.  Against this rigid definition is the 62 
Association of Official Agricultural Chemists (AOAC)-adopted version by Prosky (9), that fibres are 63 
´UHPQDQWVRISODQWFHOOVUHVLVWDQWWRGLJHVWLRQE\KXPDQGLJHVWLYHHQ]\PHVµ. This definition introduces a 64 
physiological component, insofar as resistance to digestion implicates human physiology, but its relevance 65 
to non-humans and humans with abnormal digestive capacity is questionable.  For example, LV ´ILEUHµ66 
different for animals with different profiles of digestive enzymes? Furthermore, what is the relationship 67 
between fibre and personalised medicine? For example, in the case of an inborn error of metabolism 68 
which may impair intraluminal digestion or absorption ² is this definition personal, with each of us 69 
potentially having a different profile of fibres?  Finally, it introduces a source component, in this case 70 
botanical, which raises the question of how fungi fit within this classification. The definition was further 71 
extended to include an aspect of functionality in the following Scientific Advisory Committee on 72 
Nutrition (SACN) statement: 73 
SACN consider that a material can be considered as dietary fibre if it is resistant to digestion and absorption in the small 74 
intestine and has a demonstrable physiological effect potentially associated with health benefits in the body, such as increasing 75 
stool bulk, decreasing intestinal transit time or decreasing post prandial glycaemia. Evidence only of increased fermentation in 76 
the gut should not be included under this definition, since although this has a direct effect on the microflora, it must also be 77 
shown to have a demonstrable benefit to the host to be considered as dietary fibre. 78 
(SACN Statement August 2008) 79 
This extension to the Prosky definition includes and exemplifies health benefits of fibre, yet such 80 
advantages are notoriously difficult to demonstrate and attribute. Additionally, it recognises that 81 
functionalities may occur beyond the gut, implying indirect mechanisms, although other classes of 82 
compound potentially yielding the same intermediate effectors would be excluded from this definition. 83 
The SACN statement does not reflect the source (botanical or otherwise) of fibre, but does introduce 84 
difficulties of defining fibres in potentially personalised terms. 85 
This extended cynicism about mainstream definitions could be coupled to a simple, unifying observation: 86 
bacteria cannot read research papers or position statements. The extent of compounds which reach the 87 
colon has been demonstrated, inter alia, in studies of differentially diced almond skins, which were found 88 
to yield a range of macro- and micro-nutrients (10). It can therefore be argued that the colon environment 89 
is not solely nourished by fibres, but by the totality of the ileo-caecal efflueate (ICE) - the material that 90 
passes through the ileocaecal valve, whether intact or part-digested, whether of plant, animal or fungal 91 
origin, whether polysaccharide or not. For the purposes of a review of interactions between fibres and the 92 
microbiome, this definition facilitates the full scope of potential interaction between dietary factors and 93 
the microbiome in understanding the production of the exometabolome. Our concept of ICE resembles 94 
the definition RI ILEUH SURSRVHG E\ +D ´Any dietary component that reaches the colon without being 95 
absorbed in a healthy human gutµ (11). The authors critically assimilate the overarching effects of fibre, 96 
reproduced in Figure 2 ² the division between fermentable and non-fermentable fibres. Fermentable 97 
fibres are generally progressively degraded to metabolic endproducts including short-chain fatty acids 98 
2,2 The nature of the exometabolome 99 
Major products ensuing from this fermentation are the short chain fatty acids (SCFAs) acetate, butyrate 100 
and propionate, which can be utilised for lipid or gluconeogenesis (12). SCFAs have been estimated to 101 
provide 10% of total dietary energy in humans, and host epithelial cells derive 60²70% of their energy 102 
supply from SCFA, particularly butyrate (13). Acetate and propionate are transported across the mucosa 103 
and into the hepatic portal and may be detected in the systemic circulation (14) although circulating 104 
concentrations of butyrate are disproportionately depleted in the circulation due to mucosal metabolism. 105 
Other key exometabolites include glucose, vitamins and precursors to neuropeptides. The GI tract has a 106 
panel of cell types sensing and responding to these molecules, this interaction is linked to the nervous 107 
system, and thereby the gut-brain axis (15). 108 
3. Microbiome 109 
The human GI tract houses a very complex microbial ecosystem of more than 100 trillion 110 
microorganisms, ten times greater than the total number of the human  cells in the  body. Human-111 
associated bacteria are dominated by two phyla; Firmicutes and Bacteroidetes, with Proteobacteria, 112 
Actinobacteria and Verrucomicrobia present in minor proportions (16, 17), and each phyla containing 113 
many different bacterial species (18).The gut microbiota plays an important role in metabolism, immune 114 
function, protection of the host from pathogens and bidirectional communication between the GI tract 115 
and the central nervous system (19). Dysbiosis, an aberrant state of imbalance of the gut microbiota, has 116 
been associated with a diversity of diseases and syndromes such as inflammatory bowel disease, irritable 117 
bowel syndrome, colorectal cancer, atopy, anxiety, depression, Type II diabetes and metabolic syndrome. 118 
The role of the gut microbiota in obesity has been of particular interest, especially given that the global 119 
prevalence of obesity in both children and adults is rapidly increasing (20), and is a leading cause of 120 
preventable disability and death. Obesity results from a sustained net positive energetic balance whereby 121 
energy intake exceeds energy output. In addition, host differences in the ability to store and expend 122 
energy contribute to obesity (21). A new but growing body of evidence suggests the gut microbiota, 123 
through its role as an interface between nutrients and the host, may assist body weight regulation. The gut 124 
microbiota can affect nutrient acquisition and energy harvest, as well as producing exometabolites that in 125 
turn may regulate host metabolic pathways (6, 22).  126 
Early indications that the gut microbiota was involved in obesity came when metabolically obese mice, 127 
with a mutation in the leptin gene, were shown to have a significantly different microbiota compared to 128 
mice without the mutation (23). Further investigation indicated that the ratio of Firmicutes to 129 
Bacteroidetes in the gut microbiota of obese mice was shifted in favour of Firmicutes, whilst lean mice 130 
were dominated by Bacteroidetes (24). In humans, the gut microbiota composition  can respond to 131 
changes in body weight and is altered in obese compared to non-obese individuals (18). Bacteroidetes 132 
may be responsive to calorie intake because their  levels  increase when body weight is reduced following 133 
a reduced calorie diet (25), although numerous human studies have failed to demonstrate a consistent 134 
relationship between obesity and the ratio of Firmicutes to Bacteroidetes at both the phylum- and 135 
species-level (26). 136 
Hydrogen-producing Prevotellaceae and hydrogen-utilizing methanogenic Archaea were more abundant 137 
in obese individuals suggesting a higher energy harvest in large intestine to hydrogen transfer between 138 
bacterial and archaeal species (27). Changes in the composition of the gut microbiota have been linked 139 
with (i) suppression of intestinal fasting-induced adipocyte factor (Fiaf), which is a contributing factor to 140 
enhanced fat deposition (28), (ii) increased capacity to harvest energy from food and (iii) low-grade 141 
inflammation due to activation of toll-like receptors (TLR4), endotoxin and proinflammatory cytokine 142 
production (29, 30). Approximately 5% of ingested calories are lost in the stool and urine (31). Altered 143 
nutrient load over a three-day period induced changes in the gut microbiota in both obese and non-obese 144 
individuals, despite statistically significant differences  in the composition of the lean and obese 145 
microbiome at baseline under a weight maintaining diet (32). In the case of lean subjects, a 20% increase 146 
in Firmicutes (and a corresponding decrease in Bacteroidetes) was observed over the three-day period and 147 
ZDVDVVRFLDWHGZLWKD§NFDOLQFUHDVHLQHQHUJ\DEVorption. 148 
SCFAs have been implicated in metabolic diseases, including obesity (33).  Higher levels of faecal SCFAs, 149 
mainly butyrate and propionate, have been reported in obese adults (34) and children (35), compared to 150 
lean individuals. Changes in the concentration and proportion of individual SCFA may be in line with 151 
changes in the bacterial groups present (12, 35).  152 
 153 
3. Appetite control  154 
There are two general definitions of appetite (36).  The first relates to food preference, selection and 155 
intake, and the motivation to eat, whilst the second refers to qualitative and sensory aspects of food, 156 
including the impact of environmental stimulation.  These eclipse homeostatic theories which suggested 157 
feeding corresponds to energy/nutrient deficit or excess (37), yet it is likely that a suite of homeostatic 158 
and complex non-homeostatic factors determine the overall expression of appetite.  Appetite is normally 159 
described in terms of hunger, satiation and satiety.  Hunger is associated with emptiness of the stomach, 160 
irritability and light-headedness (36).  Humans can and do, however, display hunger for other reasons: the 161 
smell, sight or even thought of food can initiate feeding (38).  Eating triggers a cascade of metabolic 162 
signals that can suppress hunger and inhibit further consumption (39).  Satiation is the point of 163 
satisfaction that results in meal termination (38, 40, 41).  Satiety is the (modifiable) post-ingestion period 164 
of repletion which influences the time of the next eating occasion (42).   165 
Appetite is controlled by multiple integrated physiological signals (See Figure 3).  Short-term signals help 166 
regulate meal initiation and termination whereas long-term, humoral signals play a central role in body 167 
weight regulation (43).  This conceptual framework for examining the impact of feeding is continually 168 
updated to represent an increasing number of factors encompassing peripheral physiological and 169 
metabolic events, and brain responses that play important roles in appetite control (44).  The GI tract 170 
responds to feeding in three integrated phases: cephalic, post-ingestive and post-absorptive, all of which 171 
depend on parasympathetic nerve transmission. The cephalic phase occurs at the point of food selection 172 
and early ingestion, and is thus stimulated by conditioned processes and organoleptic factors (45, 46).  It 173 
is held that post-ingestive satiation signals arise largely from mechanical distention, while signals from the 174 
GI tract derive predominantly from the chemical effects of food (47).  In contrast, post-absorptive effects 175 
are the result of interplay between hormones and the hypothalamic region of the brain that respond to 176 
fluctuating concentrations of nutrients in the portal vein, plasma and brain. 177 
3,1 Impact of the exometabolome on post-ingestive appetite regulation 178 
Landmark human studies have shown intestinal nutrient infusions can reduce food intake with rapid 179 
effects (48-50), indicating that satiation signals must originate from the gut as well as post-absorptively.  180 
Numerous hormones, neurotransmitters and peptides stimulate orexigenic or anorexigenic responses.  181 
Many peptide hormones are produced in the gastrointestinal tract and released in response to nutritional 182 
stimuli. Anorexigenic hormones include CCK, glucagon-like peptide-1 and -2 (GLP-1 and GLP-2), 183 
glucose-dependent insulinotropic polypeptide (GIP), oxyntomodulin, PP, peptide histidine isoleucine, 184 
peptide histidine valine, peptide YY and somatostatin)(51, 52) . Enteroendocrine (EE) cells represent less 185 
than one percent of the mucosal cell population, yet form the largest endocrine system in the human (53), 186 
and is populated by singly distributed enteroendocrine cells which release a very significant portion of 187 
appetite regulating hormones (54). (TABLE 1).  EE cells have a characteristic flask-shaped morphology 188 
and have been divided into at least sixteen cellular subtypes based on the major products they produce 189 
and secrete (55), although this model is contested and a continuum of cell types has also been proposed 190 
(56).  191 
The primary EE cell types in the colon are D cells, L cells and EnteroChromaffin (EC) cells (57). Whilst 192 
all cell types may be found along the colon, EC are the most abundant, and D cells the least, with a 193 
progressive increase in the proportion of L-cells along the caeco-rectal axis. As summarised in our review, 194 
these cells harbour peptide/hormones involved in appetitive regulation including PYY, GLP-1, GLP-2 195 
and oxyntomodulin. Intriguingly the EC subclass also contain 5HT (serotonin) and reports suggest that as 196 
PXFKDVRIWKHERG\·V+7PD\H[LVW LQWKHJXW (58)  Serotonin has been implicated in appetitive 197 
regulation, mood control and regulation of gut transit. This underwrites plausible links between luminal 198 
content, motivation to eat and wider aspects of regulation of colorectal content through modulation of 199 
transit time. These factors are explored in greater detail below.  200 
SCFAs are important signalling components within the gut-brain axis, the system of communication 201 
between the gut and the brain (19, 59) which interacts directly with gut endocrine cells, and stimulates 202 
secretion of peptide YY (PYY) by activating two G-protein-coupled receptors (GPR41 and GPR43).  EE 203 
carry free fatty acid receptors (FFARs) on their surface which have differential affinity for SCFAs and 204 
which signal the release of appetitive hormones from EEC (60). As components of the exometabolome, 205 
SCFAs therefore act as key molecules governing the sensing-signalling pathway linking luminal 206 
metabolism to appetite regulation. 207 
Our group have recently identified a further plausible mechanism of action. A significant body of 208 
literature suggests butyrate is a potent regulator of numbers of proliferating cells in the colon crypt. We 209 
recently demonstrated an inverse association between SCFA and the numbers of EEC cells in the crypt 210 
(61). Mathematical modelling suggests SCFA may modulate differentiation pathways on exit from the 211 
stem cell compartment (62). Taken together these data suggest two possible tiers of regulation of post-212 
ingestive appetite by the exometabolome: (1) an acute response in terms of regulating release of anorectic 213 
hormones; and (2) an adaptive modulation of numbers of EEC and thereby available pools of appetite-214 
regulatory hormones. 215 
3,2 Impact of the exometabolome on post-absorbtive appetite regulation 216 
Post-absorptive signals are stimulated by the entry of nutrients into the portal vein of the liver, or by 217 
fluctuating nutrient concentrations in the plasma and brain (63).  These signals act (via the hypothalamic 218 
region of the brain and vagus nerve) on the periphery and central nervous system and also interact with 219 
long-acting adiposity hormones (such as leptin) that help regulate body weight ibid. Two key areas are 220 
impacted by the exometabolome: via intestinal gluconeogenesis and through pan-systemic propionate 221 
sensing. 222 
Gluconeogenesis has until relatively recently been viewed as a primarily hepatic and renal phenomenon, 223 
and is not positively associated with health, reflecting excess energy intake. Relatively recently the 224 
intestine has been identified as a site gluconeogenesis (distinguished as Intestinal GlucoNeogenesis ² 225 
IGN) (64). IGN is regulated by both butyrate and propionate. Butyrate acts to govern the levels of IGN 226 
enzymes in the mucosa. In contrast propionate is both a substrate for IGN and is a regulator of IGN 227 
enzyme activity mediated via FFAR3 signalling (Fig 4) (65). This paper therefore also suggests emergent 228 
distinctions between the fates and activities of SCFA. Intestinally-produced glucose is transported to the 229 
HPV where it is directly sensed by sodium-coupled glucose co-transporter (66). Critically, in contrast to 230 
hepatic and renal gluconeogenesis, IGN associated with positive health outcomes (65) . 231 
Post-ingestive appetite regulation may also occur at the level of FFAR3 signalling. There is growing 232 
recognition that FFAR family receptors, including FFAR3 are expressed on a wide range of tissues 233 
including adipose, liver. The role of FFAR3 in non-gut tissue is reviewed elsewhere in this issue (67). 234 
3.3 Impact of the exometabolome on cephalic phase of appetite regulation 235 
The impact of exometabolites upon cephalic phase of appetite has not been well explored however it is 236 
reasonable to hypothesize that it does contribute to the wider mechanisms of appetite control as 237 
precedents have been shown in microbiome-mood interactions. For example: perturbations of the gut 238 
flora have been associated with schizophrenia and depression (68, 69); probiotic interventions in mouse 239 
models have demonstrated anxiolytic potential of microbial intervention (70); probiotic interventions 240 
have also shown impact upon brain activity (71) and on cognitive outcome (72). Recent reviews have 241 
suggested potential mechanisms of action, including modulation of afferent signalling by SCFA, cytokine-242 
mediated responses triggered through TLRs in the mucosa responding to the microbiome, and 243 
modulation of GABA-mediated signalling (15). As a strong evidence-base is emerging for a role of the 244 
microbiome and exometabolome in governance of mood and cognition, it seems likely that this will in 245 
time extend through to cephalic phase appetite control.  246 
 247 
4.  Modification of the microbiome by alteration of transit (the chemostat analogy) 248 
Although obesity and obesity-related disorders have been linked with alterations in the gut microbiota, 249 
less attention has been directed towards investigating lifestyle aspects of obesity, such as exercise and diet, 250 
and their effect on the microbial and physical environment of the gastrointestinal tract (73). In a recent 251 
study, elite athletes had a significantly more diverse gut microbiota compared to non-athletic size matched 252 
KLJKERG\PDVVLQGH[%0,§DQGDJHJHQGHUPDWFKHG%0,FRQWUROJURXSV (74). As the elite 253 
athlete group also consumed a significantly different diet, which provided more calories per day from 254 
carbohydrates, proteins and fat compared to the control groups, this study suggested that both diet and 255 
exercise were driving factors in changing gut microbial diversity. Exercise has also been shown to 256 
decrease transit time, particularly through the descending colon (74, 75). Previous reports have suggested 257 
however, that physical activity does not necessarily improve overall gastrointestinal transit (76).  258 
It may be convenient therefore to view the colon as a chemostat, a commonly used form of bioreactor 259 
which has been applied in microbiological settings for the determination of growth parameters. (Fig 5). In 260 
this simple model the ecosystem is fed at a specific rate (the dilution rate) which is also reflected in the 261 
rate of effluent production. The population within this system will have a growth rate (µ) proportional to 262 
the dilution rate (D). At a certain dilution rate µmax is reached ² the maximal growth rate for a particular 263 
species (in the context of an ecosystem this will be for a specific species as each will have a unique µmax ), 264 
at this point the species will start to dilute from the system. The dilution rate therefore represents an 265 
extremely strong selective pressure upon the microbiome.  As discussed in sections above, fibre intake as 266 
well as physical activity levels will influence transit time, which is analogous to the dilution rate in a 267 
chemostat. Data suggest that individuals on high-fibre diets lose more energy in faecal material than those 268 
on lower-fibre diets with an equivalent energy content (77), supporting a model whereby reduced energy 269 
harvest associates with a factor affecting transit.  270 
We therefore argue that a contributing longtundinal effect of high fibre intakes, or high physical activity, 271 
or the combination thereof is the modification of the microbiome by exerting a specific selective 272 
pressure. Contrastingly, excessive slow values for dilution rate, D, will provide opportunities for these 273 
microbial products to interact with the host epithelium, potentially increasing host energy harvest in the 274 
case of SCFAs, and elevating exposure to pro-inflammatory signalling and cytotoxic molecules. 275 
 276 
6. Summary and future directions 277 
The question of whether alterations in gut microbiota are a cause or a consequence of obesity still 278 
remains unclear, although evidence from observational and intervention studies in humans appears to 279 
suggest that both the microbiota and diet play a significant role in body weight regulation, beginning at 280 
birth. Although the utility of animal models for conducting more controlled experiments investigating the 281 
differences between the obese and lean microbiota has been established, translation to research in 282 
humans has proved less fruitful in providing a clear consensus concerning the role played by the balance 283 
between the most abundant bacterial phyla in the human gut. Indeed, the emerging evidence indicates 284 
that even the effect of individual bacterial species cannot be disregarded from study. This means that 285 
moving towards the use of high-resolution, standardised analytical techniques for surveying the gut 286 
microbiota, combined with well-designed human studies taking all of the confounding variables (e.g. age, 287 
sex, ethnicity, diet and genetic factors) into account, may allow us to identify a specific consortium of 288 
microbes that contribute to obesity, elucidate their modes of action via host and diet interactions, and 289 
evaluate novel strategies to regulate energy balance in obese individuals. Such strategies may for example 290 
include aSSURDFKHV WR PRGLI\ RU UHVWRUH ´QRUPDOLW\µ WR WKH PLUFRELRWD LQ RUGHU WR UHVWRUH HQHUJ\291 
balance. Changes in gut microbiota composition have been observed after consumption of a calorie 292 
restricted diet in overweight and obese subjects (26). Inconclusive evidence exists on the effect of 293 
supplementation with lactobacilli and bifidobacteria, alone or in combination with prebiotics, on weight 294 
management in humans (78-80). As such, intervention strategies are an attractive approach to appetite 295 
management through restoration of ecological balance in the gut. 296 
7. Key conclusions and areas for future research 297 
x Fibres are inconsistently defined and an oversight of the totality of nutrients entering the large 298 
bowel may be more informative 299 
x Perturbations in the microbiome associate with obesity and increased energy harvest. The 300 
relationship between the diet and microbiome and host health is mediated considerably by the 301 
exometabolome. 302 
x Most studies to date are associative and greater emphasis needs to be placed on longitudinal or 303 
prospective trials 304 
x The relationship between the exometabolome and the host is dynamic and multifactorial, 305 
reductionist approaches are unlikely to yield an insight into health benefits. 306 
 307 
  308 
Tables and Figure Legends 309 
Table 1: The secretory products of enteroendocrine cells of the colon and rectum and their 310 
actions 311 
Peptide Actions 
5-HT Intestinal motility; intestinal secretion; visceral sensation; appetite reduction 
Glicentin Stimulates mucosal enterocyte proliferation; inhibits gastric emptying 
GLP-1 
Incretin effect; delays gastric emptying; postprandial satiety, inhibits energy 
intake 
GLP-2 
Stimulates mucosal enterocyte proliferation, enhances digestive and absorptive 
capacities of intestine, inhibits gastric secretion 
Oxyntomodulin Inhibits gastric emptying, reduces gastric motility, inhibits food intake 
PYY 
Inhibits gastric emptying and intestinal motility; inhibits gastric acid secretion 
and pancreatic exocrine function; suppresses appetite; stimulates mucosal 
enterocyte proliferation 
Somatostatin 
Major inhibitory hormone for digestive endocrine and exocrine function; 
stimulates colonic peristalsis; potential for reducing food intake 
PYY, peptide YY; GLP-1, glucagon-like peptide 1; GLP-2, glucagon-like peptide 2.  312 
 313 
Table taken from Gunarwardene Corfe & Staton CA (2011) with additional information from (81-83) 314 
 315 
 316 
 317 
  318 
)LJXUH$FKHPLFDO2QWRORJ\IRU´)LEUHµ 319 
Accessed from ChEBI (www.chebi.ebi.ac.uk), 08.07.14 320 
 321 
Figure 2 $QDOWHUQDWLYHGHILQLWLRQRI´ILEUHµ 322 
Based on Ha et al (2000) this definition encompasses all material able to enter the colon (ICE ² Ileo 323 
Caecal Effulent), as available for microbial metabolism. Some components are readily metabolised, some 324 
highly resistant to metabolism. 325 
 326 
Fig 3 Tiers of appetite regulation by short-chain fatty acids 327 
 328 
Figure 4 Intestinal Gluconeogenesis Pathway 329 
 330 
Figure 5 Analogy between the Chemostat and the Colon 331 
Chemostat image: chemistry.about.com, colon image www.clker.com 332 
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